<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214224</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00006924</org_study_id>
    <nct_id>NCT03214224</nct_id>
  </id_info>
  <brief_title>Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific objective of this study is to validate the practice of remote pulmonary function
      testing (rPFT) conducted in the home through the use of connected mobile health devices and
      the Penn State Hershey ALS Telemanagement program.

      The second part is a comparison of respiratory outcomes in patients receiving
      telemedicine-guided respiratory assessments monthly vs. those receiving standard of care.
      This is a randomized controlled study which assesses the effects rPFT on respiratory
      outcomes, quality of life, and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objective of this study is to validate the practice of remote pulmonary function
      testing (rPFT) conducted in the home through the use of connected mobile health devices and
      the Penn State Hershey ALS Telemanagement program. The central hypothesis is that guided home
      assessment of respiratory function is a valid method for detecting respiratory insufficiency
      leading to noninvasive ventilation (NIV) recommendation. This study has the potential to
      transform the current practice of conducting breathing assessments every three months,
      resulting in timelier detection of respiratory insufficiency, thereby staining quality of
      life and lengthening survival. This protocol has the potential to demonstrate telemanagement
      exceeding the standards of ALS care.

      The study has two parts, which patients can participate in either or both. The first part is
      a self-controlled study which will enroll 40 patients from the ALS clinic. On the day of
      their clinical visit, study participants will perform both a standard PFT as well as a
      simulated rPFT, both generating three valid repetitions of forced vital capacity (FVC) and
      maximal inspiratory pressure (MIP) procedures. The simulated rPFT will mimic the practice of
      home telemonitoring by having patients be instructed by a respiratory therapist over the
      telemanagement portal while in a research room within the ALS clinic. The primary hypothesis
      is that there is no difference in the results of PFT and rPFT for respiratory assessment of
      FVC and MIP.

      The second part is a comparison of respiratory outcomes in patients receiving
      telemedicine-guided respiratory assessments monthly vs. those receiving standard of care.
      This is a randomized controlled study which assesses the effects rPFT on respiratory
      outcomes, quality of life, and survival. Forty patients with ALS will be randomized into two
      arms, both receiving standard respiratory assessments for pulmonary function every three
      months, and the experimental group additionally receiving rPFTs in the interim months over
      the course of a year. The primary hypothesis is that home respiratory assessment enables
      thresholds for NIV recommendation to be met in the experimental group significantly closer to
      the initiation criteria, at a time when quality of life is higher, compared to the control
      group.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Restrictions on recruitment and site visits due to COVID19
  </why_stopped>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study has two parts
A self-controlled validation study of experimental remote PFT assessment vs standard of care (non-randomized)
A longitudinal parallel group study of repeated measures of remote PFTs and their impact on care delivery</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Part 1) Standard PFT - Forced Vital Capacity</measure>
    <time_frame>One administration - 10 minutes</time_frame>
    <description>Respiratory therapist will administer three valid maneuvers of forced vital capacity (FVC) The best FVC value is the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 1) Standard PFT - Maximal Inspiratory Pressure</measure>
    <time_frame>One administration - 10 minutes</time_frame>
    <description>Respiratory therapist will administer three valid maneuvers of maximal inspiratory pressure (MIP). The best MIP value is the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 1) Remote PFT - Forced Vital Capacity</measure>
    <time_frame>One administration - 10 minutes</time_frame>
    <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid FVC maneuvers. The best FVC value is the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 1) Remote PFT - Maximal Inspiratory Pressure</measure>
    <time_frame>One administration - 10 minutes</time_frame>
    <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid MIP maneuvers. The best MIP value is the outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) Longitudinal Standard PFT - FVC</measure>
    <time_frame>10 minute assessment done every three months for a year</time_frame>
    <description>The result of standard FVC testing during clinical visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) Longitudinal Standard PFT - MIP</measure>
    <time_frame>10 minute assessment done approximately every 3 months for one year</time_frame>
    <description>The result of standard MIP testing during clinical visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) Longitudinal Remote PFT - FVC</measure>
    <time_frame>15 minute assessment done weekly for one year</time_frame>
    <description>The results of remote FVC testing during in between clinical visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Part 2) Longitudinal Remote PFT - MIP</measure>
    <time_frame>15 minute assessment done weekly for one year</time_frame>
    <description>The results of remote MIP testing during in between clinical visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Patient and Caregiver Reported Outcomes</measure>
    <time_frame>10 minute survey administered following completion of standard and remote PFT of Part 1</time_frame>
    <description>Survey responses from the patient/caregiver pair. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 1) Therapist Reported Outcomes</measure>
    <time_frame>10 minute survey administered following completion of standard and remote PFT of Part 1</time_frame>
    <description>Survey responses from the respiratory therapist. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Survival Data</measure>
    <time_frame>During and one year following primary data collection period.</time_frame>
    <description>Study participants will be followed after completion of study procedures and date of death, if available,will be recorded. Survival rates between the experimental and control groups will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>remote PFT (rPFT) longitudinal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo regular interim remote pulmonary function testing using the telemedicine interface and study equipment. In addition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remote PFT (rPFT) validation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>remote pulmonary function testing</intervention_name>
    <description>Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
    <arm_group_label>remote PFT (rPFT) longitudinal</arm_group_label>
    <arm_group_label>remote PFT (rPFT) validation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard pulmonary function testing</intervention_name>
    <description>Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
    <arm_group_label>remote PFT (rPFT) longitudinal</arm_group_label>
    <arm_group_label>remote PFT (rPFT) validation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1

        Patients:

          1. Possess a diagnosis of definite, probable, probable laboratory-supported, or possible
             ALS by revised El Escorial research criteria [Brooks2000].

          2. Be 18 years of age or older.

          3. Have a caregiver available to participate in the study

        Caregivers:

          1. Be 18 years of age or older, of either gender.

          2. Be able and willing to provide informed consent.

        Respiratory Therapist

          1. Be a member of the Hershey Medical Center ALS multidisciplinary care team.

          2. Be able and willing to provide verbal informed consent after receiving a summary
             explanation of research (SER).

        Part 2 imposes additional inclusion criteria for patients only.

        Patients:

        4) Symptom onset within the last three years. 5) Intent to attend the Penn State Hershey
        ALS clinic every three months for the next year.

        6) Have home wireless internet service sufficient for engaging in telemedicine sessions.

        Exclusion Criteria:

          -  Exclusion criteria are the same for both parts of the study.

        Patients:

          1. Use of NIV or diaphragm pacer at time of obtaining informed consent.

          2. FVC ≤50% predicted or MIP &gt; -60 cm H2O.

          3. ALS Functional Rating Scale (ALSFRS-R) [Cedarbaum1999] score on day of screening of ≥2
             on items for speech, swallowing, and salivation. These items are indicators of bulbar
             dysfunction, which limits the reliability of PFT administration.

          4. Cognitive impairment, as judged by the ALS clinic neurologist, that prevents
             participation in the study.

        Caregivers: None

        Respiratory Therapists: None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hershey Medical Center ALS Clinic</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <results_first_submitted>January 14, 2019</results_first_submitted>
  <results_first_submitted_qc>March 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2019</results_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Zachary Simmons</investigator_full_name>
    <investigator_title>Professor of Neurology and Humanities</investigator_title>
  </responsible_party>
  <keyword>Telemedicine</keyword>
  <keyword>Pulmonary Function Testing</keyword>
  <keyword>Telehealth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan at this time to share data with other researchers</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03214224/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03214224/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Recruitment has not yet begun for the second, randomized phase of the protocol, which involves enrollment into the standard pulmonary function testing (PFT) and remote PFT study arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard PFT</title>
          <description>Those randomized to the control group will undergo standard pulmonary function testing as part of standard clinical procedure. In addition, they will complete monthly surveys pertaining to respiratory function.
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
        </group>
        <group group_id="P2">
          <title>Remote PFT (rPFT)</title>
          <description>Those randomized to the experimental group will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo regular interim remote pulmonary function testing using the telemedicine interface and study equipment. In addition, they will complete monthly surveys pertaining to respiratory function.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
        </group>
        <group group_id="P3">
          <title>Remote PFT (rPFT) Validation</title>
          <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Validation Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="49">Subjects did both standard and remote assessments in the validation study. Total enrollment 49.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="40">3 therapists enrolled. 3 controls enrolled but not included in analysis set. 3 patients also.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Practice controls or therapists</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Longitudinal PFT Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only patients who completed validation procedures are included (40 total). Recruitment has not yet begun for the second, randomized phase of the protocol, which involves enrollment into the standard PFT and remote PFT strudy arms.</population>
      <group_list>
        <group group_id="B1">
          <title>Standard PFT</title>
          <description>Those randomized to the control group will undergo standard pulmonary function testing as part of standard clinical procedure. In addition, they will complete monthly surveys pertaining to respiratory function.
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
        </group>
        <group group_id="B2">
          <title>Remote PFT (rPFT)</title>
          <description>Those randomized to the experimental group will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo regular interim remote pulmonary function testing using the telemedicine interface and study equipment. In addition, they will complete monthly surveys pertaining to respiratory function.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
        </group>
        <group group_id="B3">
          <title>Remote PFT (rPFT) Validation</title>
          <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="61.5" spread="9.7"/>
                    <measurement group_id="B4" value="61.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALS Functional Rating Scale - Revised (ALSFRS-R)</title>
          <description>Scale that measures physical function in bulbar, fine motor, gross motor, and breathing domains. Total score ranges from 0-48. Higher numbers indicate normal function. Lower numbers indicate impaired function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="31.3" spread="7.9"/>
                    <measurement group_id="B4" value="31.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Symptom Onset</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="59.2" spread="56.8"/>
                    <measurement group_id="B4" value="59.2" spread="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>ALS</title>
                  <measurement_list>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PLS</title>
                  <measurement_list>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PMA</title>
                  <measurement_list>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>(Part 1) Standard PFT - Forced Vital Capacity</title>
        <description>Respiratory therapist will administer three valid maneuvers of forced vital capacity (FVC) The best FVC value is the outcome.</description>
        <time_frame>One administration - 10 minutes</time_frame>
        <population>40 patients taking part in validation study</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Standard PFT - Forced Vital Capacity</title>
          <description>Respiratory therapist will administer three valid maneuvers of forced vital capacity (FVC) The best FVC value is the outcome.</description>
          <population>40 patients taking part in validation study</population>
          <units>Percent Predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 1) Standard PFT - Maximal Inspiratory Pressure</title>
        <description>Respiratory therapist will administer three valid maneuvers of maximal inspiratory pressure (MIP). The best MIP value is the outcome.</description>
        <time_frame>One administration - 10 minutes</time_frame>
        <population>40 patients taking part in validation study</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Standard PFT - Maximal Inspiratory Pressure</title>
          <description>Respiratory therapist will administer three valid maneuvers of maximal inspiratory pressure (MIP). The best MIP value is the outcome.</description>
          <population>40 patients taking part in validation study</population>
          <units>cm water</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.7" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 1) Remote PFT - Forced Vital Capacity</title>
        <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid FVC maneuvers. The best FVC value is the outcome.</description>
        <time_frame>One administration - 10 minutes</time_frame>
        <population>40 patients taking part in validation study</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Remote PFT - Forced Vital Capacity</title>
          <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid FVC maneuvers. The best FVC value is the outcome.</description>
          <population>40 patients taking part in validation study</population>
          <units>Percent predicted of FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 1) Remote PFT - Maximal Inspiratory Pressure</title>
        <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid MIP maneuvers. The best MIP value is the outcome.</description>
        <time_frame>One administration - 10 minutes</time_frame>
        <population>40 patients taking part in validation study</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Remote PFT - Maximal Inspiratory Pressure</title>
          <description>Respiratory therapist will use the telehealth interface to guide the patient and caregiver to self-administer three valid MIP maneuvers. The best MIP value is the outcome.</description>
          <population>40 patients taking part in validation study</population>
          <units>cm water</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.2" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 2) Longitudinal Standard PFT - FVC</title>
        <description>The result of standard FVC testing during clinical visits</description>
        <time_frame>10 minute assessment done every three months for a year</time_frame>
        <posting_date>09/2020</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 2) Longitudinal Standard PFT - MIP</title>
        <description>The result of standard MIP testing during clinical visits</description>
        <time_frame>10 minute assessment done approximately every 3 months for one year</time_frame>
        <posting_date>09/2020</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 2) Longitudinal Remote PFT - FVC</title>
        <description>The results of remote FVC testing during in between clinical visits.</description>
        <time_frame>15 minute assessment done weekly for one year</time_frame>
        <posting_date>09/2020</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Part 2) Longitudinal Remote PFT - MIP</title>
        <description>The results of remote MIP testing during in between clinical visits.</description>
        <time_frame>15 minute assessment done weekly for one year</time_frame>
        <posting_date>09/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Part 1) Patient and Caregiver Reported Outcomes</title>
        <description>Survey responses from the patient/caregiver pair. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
        <time_frame>10 minute survey administered following completion of standard and remote PFT of Part 1</time_frame>
        <population>One subject did not complete the survey</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Patient and Caregiver Reported Outcomes</title>
          <description>Survey responses from the patient/caregiver pair. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
          <population>One subject did not complete the survey</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread=".58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced Vital Capacity Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal Inspiratory Pressure Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread=".59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Part 1) Therapist Reported Outcomes</title>
        <description>Survey responses from the respiratory therapist. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
        <time_frame>10 minute survey administered following completion of standard and remote PFT of Part 1</time_frame>
        <population>There were three therapists who produced 35 separate survey responses. Responses from 5 patient interactions were not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Remote PFT (rPFT) Validation</title>
            <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
          </group>
        </group_list>
        <measure>
          <title>(Part 1) Therapist Reported Outcomes</title>
          <description>Survey responses from the respiratory therapist. Likert-type scales are used to generate subscores pertaining to: General Acceptability, Forced Vital Capacity Acceptability, and Maximal Inspiratory Pressure Acceptability.
Subscales (evaluated separately):
General Acceptability [0-5 (worst-best)] Forced Vital Capacity Acceptability [0-5 (worst-best) Maximal Inspiratory Pressure Acceptability [0-5 (worst-best)]</description>
          <population>There were three therapists who produced 35 separate survey responses. Responses from 5 patient interactions were not available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread=".50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced Vital Capacity Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread=".63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal Inspiratory Pressure Acceptability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread=".44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Part 2) Survival Data</title>
        <description>Study participants will be followed after completion of study procedures and date of death, if available,will be recorded. Survival rates between the experimental and control groups will be compared.</description>
        <time_frame>During and one year following primary data collection period.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the validation study, adverse event data was collected over the period of the procedures, approximately 20 minutes.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Remote PFT (rPFT) Validation</title>
          <description>Those in the first part of the study will perform both standard and remote PFT assessments in order to validate the procedure.
remote pulmonary function testing: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
standard pulmonary function testing: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Geronimo</name_or_title>
      <organization>Penn State College of Medicine</organization>
      <phone>717-531-0003 ext 282576</phone>
      <email>geronimo@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

